Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabigerol oil in adolescents with attention-deficit/hyperactivity disorder
RBR-3smxct4Phase 2Not yet recruiting
- Sponsor
- Estácio
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cannabigerol in attention deficit hyperactivity disorder (ADHD), sponsored by Estácio. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
cannabigerol
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on RBR-3smxct4.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-3smxct4.